{"filing":{"accession_number":"0001493152-26-035864","cik":"0001763950","ticker":"LTRN","company_name":"Lantern Pharma Inc.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226035864/form8-k.htm"},"events":[{"id":23258,"run_id":21028,"accession_number":"0001493152-26-035864","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Lantern Pharma announced the formal establishment of Open-Medicine AI as a separate company to commercialize its multi-agent AI co-scientist platform (formerly withZeta.ai), with execution of commercial licensing agreements and Board approval. This represents a significant strategic and operational restructuring—the spin-out of a material business line with dedicated funding and valuation path—but does not constitute a traditional M\u0026A transaction, equity issuance, or other specifically-named event type. The disclosure emphasizes operational focus, market expansion, and commercial positioning rather than a change in control or divestiture.","company_name":"Lantern Pharma Inc.","ticker":"LTRN","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":23445,"accession_number":"0001493152-26-035864","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Lantern Pharma announced the formal establishment of Open-Medicine AI as a separate company to commercialize its multi-agent AI co-scientist platform (formerly withZeta.ai), with execution of commercial licensing agreements and Board approval. This represents a significant strategic and operational restructuring—the spin-out of a material business line with dedicated funding and valuation path—but does not constitute a traditional M\u0026A transaction, equity issuance, or other specifically-named event type. The disclosure emphasizes operational focus, market expansion, and commercial positioning rather than a change in control or divestiture.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:53:51.297743+00:00","company_name":"Lantern Pharma Inc.","ticker":"LTRN","filing_date":"2026-08-03"}]}